Cargando…

Immune System Disorders, Cancer and Viral Infections: A New Treatment Opportunity for the Immune Checkpoint Inhibitors

The relationship between viral infections and cancer is well known and has been established for decades. Multiple tumours are generated from alterations secondary to viral infections 2 resulting from a dysregulation of the immune system in many cases. Certain causal relationships, such as that betwe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Olivares-Hernández, Alejandro, Figuero-Pérez, Luis, Miramontes-González, José Pablo, López-Gutiérrez, Álvaro, González-Sarmiento, Rogelio, Cruz-Hernández, Juan Jesús, Fonseca-Sánchez, Emilio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8709484/ https://www.ncbi.nlm.nih.gov/pubmed/34947931 http://dx.doi.org/10.3390/life11121400

Ejemplares similares

Resistance to Immune Checkpoint Inhibitors Secondary to Myeloid-Derived Suppressor Cells: A New Therapeutic Targeting of Haematological Malignancies
por: Olivares-Hernández, Alejandro, et al.
Publicado: (2021)

Immune checkpoint inhibitors in non-small cell lung cancer: from current perspectives to future treatments—a systematic review
por: Olivares-Hernández, Alejandro, et al.
Publicado: (2023)

Dopamine Receptors and the Kidney: An Overview of Health- and Pharmacological-Targeted Implications
por: Olivares-Hernández, Alejandro, et al.
Publicado: (2021)

Influence of DNA Mismatch Repair (MMR) System in Survival and Response to Immune Checkpoint Inhibitors (ICIs) in Non-Small Cell Lung Cancer (NSCLC): Retrospective Analysis
por: Olivares-Hernández, Alejandro, et al.
Publicado: (2022)

Cardiotoxicity Secondary to Immune Checkpoint Inhibitors in the Elderly: Safety in Real-World Data
por: Toribio-García, Irene, et al.
Publicado: (2023)

The relationship between PARP inhibitors with the relapse and leukemisation of lymphomas: a case report
por: Navalón-Jiménez, Marta, et al.
Publicado: (2023)

Response to Treatment with an Anti-Interleukin-6 Receptor Antibody (Tocilizumab) in a Patient with Hemophagocytic Syndrome Secondary to Immune Checkpoint Inhibitors
por: Olivares-Hernández, Alejandro, et al.
Publicado: (2021)

Anakinra as a potential alternative in the treatment of severe acute respiratory infection associated with SARS-CoV-2 refractory to tocilizumab()
por: Figuero-Pérez, Luis, et al.
Publicado: (2021)

Anakinra, una alternativa potencial en el tratamiento de la infección respiratoria grave por SARS-CoV-2 refractaria a tocilizumab
por: Figuero-Pérez, Luis, et al.
Publicado: (2021)

Immune Checkpoints in Viral Infections
por: Cai, Huiming, et al.
Publicado: (2020)

Uso de anakinra en el tratamiento de la infección respiratoria grave por SARS-CoV-2
por: Figuero-Pérez, Luis, et al.
Publicado: (2023)

Use of anakinra in the treatment of SARS-CoV-2 severe respiratory infection()
por: Figuero-Pérez, Luis, et al.
Publicado: (2023)

Immune Checkpoint Inhibitors for the Therapy of Thymoma
por: Quilez, Alicia, et al.
Publicado: (2020)

Immune checkpoint inhibitors in lymphoma: challenges and opportunities
por: Hatic, Haris, et al.
Publicado: (2021)

DNA Damage Response Alterations in Ovarian Cancer: From Molecular Mechanisms to Therapeutic Opportunities
por: Ovejero-Sánchez, María, et al.
Publicado: (2023)

Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Opportunities and Challenges
por: Liu, Xiufeng, et al.
Publicado: (2019)

Immune checkpoints in thymic epithelial tumors: challenges and opportunities
por: Girard, Nicolas
Publicado: (2019)

Unravelling soluble immune checkpoints in chronic lymphocytic leukemia: Physiological immunomodulators or immune dysfunction
por: Landeira-Viñuela, Alicia, et al.
Publicado: (2022)

Predictive biomarkers for immune checkpoint blockade and opportunities for combination therapies
por: Shen, Hongxing, et al.
Publicado: (2019)

Assessing the risk of cardiovascular events in patients receiving immune checkpoint inhibitors
por: Torrente, María, et al.
Publicado: (2022)

The Emerging Role of NK Cells in Immune Checkpoint Blockade
por: Martinez-Perez, Alejandra, et al.
Publicado: (2022)

Hematologic complications of immune checkpoint inhibitors
por: Kroll, Michael H., et al.
Publicado: (2022)

Inhibitory immune checkpoints cause exhaustion of viral immunity in coronary artery disease
Publicado: (2022)

Immune Checkpoint Inhibitors: A New Opportunity in the Treatment of Ovarian Cancer?
por: Mittica, Gloria, et al.
Publicado: (2016)

Immune checkpoint inhibitors for small cell lung cancer: opportunities and challenges
por: Regzedmaa, Orgilmaa, et al.
Publicado: (2019)

Immune checkpoint inhibitors in esophageal squamous cell carcinoma: progress and opportunities
por: Jiao, Ruidi, et al.
Publicado: (2019)

Overcoming resistance to immune checkpoint inhibitors in hepatocellular carcinoma: Challenges and opportunities
por: Xie, Qingqing, et al.
Publicado: (2022)

Immunity to α-Gal: The Opportunity for Malaria and Tuberculosis Control
por: Cabezas-Cruz, Alejandro, et al.
Publicado: (2017)

Immune Checkpoint Inhibitor-Induced Colitis: How Long Does the Threat Last?
por: Calle Sarmiento, Paola Michelle
Publicado: (2023)

Angiogenesis and immune checkpoint dual blockade: Opportunities and challenges for hepatocellular carcinoma therapy
por: Li, Si-Qi, et al.
Publicado: (2022)

Tumor fitness, immune exhaustion and clinical outcomes: impact of immune checkpoint inhibitors
por: Bubie, Adrian, et al.
Publicado: (2020)

The Impact of Tregs on the Anticancer Immunity and the Efficacy of Immune Checkpoint Inhibitor Therapies
por: González-Navajas, Jose M., et al.
Publicado: (2021)

Quantifying PD-L1 Expression to Monitor Immune Checkpoint Therapy: Opportunities and Challenges
por: Nimmagadda, Sridhar
Publicado: (2020)

Obstacles for T-lymphocytes in the tumour microenvironment: Therapeutic challenges, advances and opportunities beyond immune checkpoint
por: Verma, Navin Kumar, et al.
Publicado: (2022)

Immune checkpoint inhibitors: here to stay
por: Carvalho, Filomena Marino, et al.
Publicado: (2023)

Understanding the function and dysfunction of the immune system in lung cancer: the role of immune checkpoints
por: Karachaliou, Niki, et al.
Publicado: (2015)

Partners in crime: The feedback loop between metabolic reprogramming and immune checkpoints in the tumor microenvironment
por: Benito-Lopez, Jesus J., et al.
Publicado: (2023)

Neurologic Toxicity of Immune Checkpoint Inhibitors: A Review of Literature
por: Albarrán, Víctor, et al.
Publicado: (2022)

On the use of immune checkpoint inhibitors in patients with viral infections including COVID-19
por: Gambichler, Thilo, et al.
Publicado: (2020)

Viral status, immune microenvironment and immunological response to checkpoint inhibitors in hepatocellular carcinoma
por: Ho, Won Jin, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_gtbv3nk81g197bkprkf515qq8m